Silk Road Medical (SILK) Stock Forecast, Price Target & Predictions
SILK Stock Forecast
Silk Road Medical stock forecast is as follows: an average price target of $30.58 (represents a 11.24% upside from SILK’s last price of $27.49) and a rating consensus of 'Buy', based on 7 wall street analysts offering a 1-year stock forecast.
SILK Price Target
The average price target for Silk Road Medical (SILK) is $30.58 based on 1-year price targets from 7 Wall Street analysts in the past 3 months, with a price target range of $46.00 to $20.00. This represents a potential 11.24% upside from SILK's last price of $27.49.
SILK Analyst Ratings
According to 7 Wall Street analysts, Silk Road Medical's rating consensus is 'Buy'. The analyst rating breakdown for SILK stock is 0 'Strong Buy' (0.00%), 4 'Buy' (57.14%), 3 'Hold' (42.86%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Silk Road Medical Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Jun 18, 2024 | Frank Takkinen | Lake Street | $27.50 | $26.80 | 2.59% | 0.04% |
| Jun 14, 2024 | David Toung | Argus Research | $32.00 | $21.19 | 51.01% | 16.41% |
| May 01, 2024 | Adam Maeder | Piper Sandler | $20.00 | $18.26 | 9.53% | -27.25% |
| Apr 03, 2024 | Frank Takkinen | Loop Capital Markets | $28.00 | $17.43 | 60.64% | 1.86% |
| Mar 07, 2024 | Steve Silver | Argus Research | $24.00 | $15.98 | 50.19% | -12.70% |
| Sep 06, 2023 | Suraj Kalia | Oppenheimer | $30.00 | $19.14 | 56.74% | 9.13% |
| Jul 18, 2022 | - | Stifel Nicolaus | $46.00 | $39.36 | 16.86% | 67.33% |
| Apr 06, 2022 | Adam Maeder | Piper Sandler | $43.00 | $42.97 | 0.07% | 56.42% |
The latest Silk Road Medical stock forecast, released on Jun 18, 2024 by Frank Takkinen from Lake Street, set a price target of $27.50, which represents a 2.59% increase from the stock price at the time of the forecast ($26.80), and a 0.04% increase from SILK last price ($27.49).
Silk Road Medical Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 1 | 5 |
| Avg Price Target | - | $27.50 | $26.30 |
| Last Closing Price | $27.49 | $27.49 | $27.49 |
| Upside/Downside | -100.00% | 0.04% | -4.33% |
In the current month, the average price target of Silk Road Medical stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Silk Road Medical's last price of $27.49. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Jun 18, 2024 | Lake Street | Buy | Hold | Downgrade |
| May 01, 2024 | Piper Sandler | Neutral | Neutral | Hold |
| Apr 29, 2024 | Lake Street | Buy | Buy | Hold |
| Apr 03, 2024 | Lake Street | Buy | Buy | Hold |
| Jan 19, 2024 | Raymond James | - | Buy | Upgrade |
| Sep 06, 2023 | Oppenheimer | - | Outperform | Initialise |
| Jul 12, 2023 | J.P. Morgan | - | Neutral | Downgrade |
| May 22, 2023 | Argus Research | Buy | Buy | Hold |
| May 15, 2023 | Wolfe Research | - | Underperform | Downgrade |
| Apr 03, 2023 | Citigroup | Neutral | Buy | Upgrade |
Silk Road Medical's last stock rating was published by Lake Street on Jun 18, 2024. The company Downgrade its SILK rating from "Buy" to "Hold".
Silk Road Medical Financial Forecast
Silk Road Medical Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | $44.44M | $45.30M | $40.13M | $40.07M | $37.37M | - | $28.02M | $28.27M | $24.70M | $26.46M | $22.05M | $21.13M | $20.07M | $15.09M | $18.93M | $18.63M | $17.03M | $14.93M | $12.77M |
| Avg Forecast | $58.94M | $55.20M | $55.16M | $52.45M | $50.91M | $48.75M | $49.74M | $44.67M | $41.93M | $44.53M | $43.24M | $40.69M | $37.35M | $33.40M | $31.04M | $27.10M | $25.91M | $24.32M | $25.34M | $21.29M | $21.35M | $19.59M | $9.47M | $17.33M | $17.97M | $15.90M | $13.64M | $12.19M |
| High Forecast | $61.02M | $57.14M | $57.11M | $54.30M | $52.71M | $49.62M | $51.50M | $46.25M | $42.34M | $46.10M | $44.77M | $42.13M | $38.67M | $34.58M | $31.04M | $27.47M | $26.27M | $24.65M | $25.69M | $21.59M | $21.64M | $19.86M | $9.60M | $17.57M | $18.22M | $16.12M | $13.83M | $12.36M |
| Low Forecast | $57.60M | $53.94M | $53.91M | $51.25M | $49.75M | $47.60M | $48.61M | $43.66M | $41.70M | $43.52M | $42.26M | $39.77M | $36.50M | $32.64M | $31.04M | $26.45M | $25.29M | $23.74M | $24.74M | $20.79M | $20.84M | $19.12M | $9.24M | $16.91M | $17.54M | $15.52M | $13.31M | $11.90M |
| # Analysts | 1 | 1 | 1 | 1 | 2 | 4 | 2 | 4 | 7 | 5 | 6 | 3 | 2 | 2 | 2 | 3 | 7 | 4 | 6 | 4 | 7 | 4 | 6 | 4 | 6 | 3 | 5 | 3 |
| Surprise % | - | - | - | - | - | - | - | - | - | 1.00% | 1.05% | 0.99% | 1.07% | 1.12% | - | 1.03% | 1.09% | 1.02% | 1.04% | 1.04% | 0.99% | 1.02% | 1.59% | 1.09% | 1.04% | 1.07% | 1.09% | 1.05% |
Silk Road Medical's average Quarter revenue forecast for Dec 23 based on 7 analysts is $41.93M, with a low forecast of $41.70M, and a high forecast of $42.34M. SILK's average Quarter revenue forecast represents a -5.63% decrease compared to the company's last Quarter revenue of $44.44M (Sep 23).
Silk Road Medical EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 2 | 4 | 2 | 4 | 7 | 5 | 6 | 3 | 2 | 2 | 2 | 3 | 7 | 4 | 6 | 4 | 7 | 4 | 6 | 4 | 6 | 3 | 5 | 3 |
| EBITDA | - | - | - | - | - | - | - | - | - | $-13.67M | $-11.77M | $-13.79M | $-10.88M | $-8.61M | - | $-16.06M | $-13.49M | $-12.76M | $-9.45M | $-9.67M | $-15.59M | $-8.75M | $-8.82M | $-8.41M | $-6.75M | $-6.51M | $-10.44M | $-22.47M |
| Avg Forecast | $-24.87M | $-23.29M | $-23.27M | $-22.13M | $-21.48M | $-20.57M | $-20.98M | $-15.59M | $-17.69M | $-18.79M | $-18.24M | $-14.17M | $-15.76M | $-9.96M | $-13.09M | $-12.88M | $-11.24M | $-9.05M | $-10.99M | $-11.66M | $-9.01M | $-7.82M | $-10.01M | $-8.14M | $-6.75M | $-6.75M | $-5.10M | $-1.23B |
| High Forecast | $-24.30M | $-22.76M | $-22.74M | $-21.62M | $-20.99M | $-20.08M | $-20.51M | $-12.47M | $-17.59M | $-18.36M | $-17.83M | $-11.34M | $-15.40M | $-7.97M | $-13.09M | $-10.31M | $-8.99M | $-7.24M | $-8.79M | $-9.33M | $-8.79M | $-6.25M | $-8.01M | $-6.51M | $-5.40M | $-5.40M | $-4.08M | $-984.86M |
| Low Forecast | $-25.74M | $-24.11M | $-24.09M | $-22.91M | $-22.24M | $-20.93M | $-21.73M | $-18.70M | $-17.86M | $-19.45M | $-18.89M | $-17.00M | $-16.31M | $-11.95M | $-13.09M | $-15.46M | $-13.49M | $-10.86M | $-13.18M | $-13.99M | $-9.13M | $-9.38M | $-12.01M | $-9.77M | $-8.10M | $-8.10M | $-6.12M | $-1.48B |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.73% | 0.65% | 0.97% | 0.69% | 0.86% | - | 1.25% | 1.20% | 1.41% | 0.86% | 0.83% | 1.73% | 1.12% | 0.88% | 1.03% | 1.00% | 0.96% | 2.05% | 0.02% |
undefined analysts predict SILK's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Silk Road Medical's previous annual EBITDA (undefined) of $NaN.
Silk Road Medical Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 2 | 4 | 2 | 4 | 7 | 5 | 6 | 3 | 2 | 2 | 2 | 3 | 7 | 4 | 6 | 4 | 7 | 4 | 6 | 4 | 6 | 3 | 5 | 3 |
| Net Income | - | - | - | - | - | - | - | - | - | $-12.79M | $-13.48M | $-16.01M | $-12.60M | $-11.41M | - | $-17.40M | $-15.33M | $-13.88M | $-10.54M | $-10.69M | $-16.76M | $-10.31M | $-10.35M | $-9.94M | $-8.29M | $-8.01M | $-11.96M | $-24.16M |
| Avg Forecast | $-11.59M | $-12.48M | $-12.92M | $-15.21M | $-13.98M | $-15.11M | $-14.81M | $-16.74M | $-16.67M | $-13.97M | $-15.42M | $-15.21M | $-14.94M | $-10.84M | $-17.62M | $-13.83M | $-12.24M | $-9.85M | $-12.25M | $-12.89M | $-10.91M | $-9.21M | $-11.75M | $-9.62M | $-8.29M | $-8.30M | $-5.85M | $-1.32B |
| High Forecast | $-11.25M | $-12.11M | $-12.53M | $-14.76M | $-13.57M | $-13.43M | $-14.37M | $-13.39M | $-12.92M | $-13.56M | $-14.97M | $-12.17M | $-14.50M | $-8.67M | $-17.62M | $-11.07M | $-9.80M | $-7.88M | $-9.80M | $-10.31M | $-10.58M | $-7.37M | $-9.40M | $-7.70M | $-6.63M | $-6.64M | $-4.68M | $-1.06B |
| Low Forecast | $-12.12M | $-13.05M | $-13.51M | $-15.91M | $-14.62M | $-16.79M | $-15.49M | $-20.08M | $-23.33M | $-14.61M | $-16.13M | $-18.26M | $-15.62M | $-13.01M | $-17.62M | $-16.60M | $-14.69M | $-11.82M | $-14.70M | $-15.47M | $-11.11M | $-11.05M | $-14.10M | $-11.54M | $-9.95M | $-9.96M | $-7.02M | $-1.59B |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.92% | 0.87% | 1.05% | 0.84% | 1.05% | - | 1.26% | 1.25% | 1.41% | 0.86% | 0.83% | 1.54% | 1.12% | 0.88% | 1.03% | 1.00% | 0.96% | 2.05% | 0.02% |
Silk Road Medical's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. SILK's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Silk Road Medical SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 2 | 4 | 2 | 4 | 7 | 5 | 6 | 3 | 2 | 2 | 2 | 3 | 7 | 4 | 6 | 4 | 7 | 4 | 6 | 4 | 6 | 3 | 5 | 3 |
| SG&A | - | - | - | - | - | - | - | - | - | $36.01M | $35.83M | $34.08M | $32.52M | $28.82M | - | $27.27M | $27.59M | $25.05M | $22.55M | $21.19M | $20.87M | $19.20M | $15.76M | $19.69M | $18.16M | $17.06M | $14.13M | $13.87M |
| Avg Forecast | $54.34M | $50.88M | $50.85M | $48.35M | $46.93M | $44.94M | $45.86M | $27.37M | $38.66M | $41.05M | $39.86M | $24.88M | $34.43M | $19.55M | $28.61M | $22.62M | $23.00M | $17.78M | $23.36M | $19.63M | $19.68M | $17.14M | $8.73M | $15.97M | $16.57M | $14.66M | $6.91M | $11.24M |
| High Forecast | $56.25M | $52.68M | $52.65M | $50.06M | $48.59M | $45.75M | $47.48M | $32.84M | $39.03M | $42.50M | $41.27M | $29.86M | $35.65M | $23.47M | $28.61M | $27.14M | $27.59M | $21.33M | $23.68M | $19.90M | $19.95M | $20.57M | $8.85M | $16.20M | $16.80M | $14.86M | $8.29M | $11.39M |
| Low Forecast | $53.10M | $49.73M | $49.70M | $47.25M | $45.87M | $43.89M | $44.81M | $21.89M | $38.45M | $40.12M | $38.96M | $19.90M | $33.65M | $15.64M | $28.61M | $18.09M | $18.40M | $14.22M | $22.80M | $19.16M | $19.21M | $13.72M | $8.52M | $15.59M | $16.17M | $14.31M | $5.53M | $10.97M |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.88% | 0.90% | 1.37% | 0.94% | 1.47% | - | 1.21% | 1.20% | 1.41% | 0.97% | 1.08% | 1.06% | 1.12% | 1.81% | 1.23% | 1.10% | 1.16% | 2.05% | 1.23% |
Silk Road Medical's average Quarter SG&A projection for Dec 23 is $38.66M, based on 7 Wall Street analysts, with a range of $38.45M to $39.03M. The forecast indicates a 7.35% rise compared to SILK last annual SG&A of $36.01M (Sep 23).
Silk Road Medical EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 2 | 4 | 2 | 4 | 7 | 5 | 6 | 3 | 2 | 2 | 2 | 3 | 7 | 4 | 6 | 4 | 7 | 4 | 6 | 4 | 6 | 3 | 5 | 3 |
| EPS | - | - | - | - | - | - | - | - | - | $-0.33 | $-0.35 | $-0.42 | $-0.33 | $-0.32 | - | $-0.50 | $-0.44 | $-0.40 | $-0.31 | $-0.31 | $-0.49 | $-0.31 | $-0.32 | $-0.32 | $-0.27 | $-0.26 | $-0.42 | $-0.84 |
| Avg Forecast | $-0.29 | $-0.32 | $-0.33 | $-0.38 | $-0.35 | $-0.38 | $-0.37 | $-0.40 | $-0.42 | $-0.35 | $-0.39 | $-0.40 | $-0.38 | $-0.45 | $-0.45 | $-0.37 | $-0.36 | $-0.33 | $-0.37 | $-0.39 | $-0.28 | $-0.29 | $-0.37 | $-0.31 | $-0.27 | $-0.27 | $-0.27 | $-0.32 |
| High Forecast | $-0.28 | $-0.31 | $-0.32 | $-0.37 | $-0.34 | $-0.34 | $-0.36 | $-0.39 | $-0.33 | $-0.34 | $-0.38 | $-0.39 | $-0.37 | $-0.44 | $-0.45 | $-0.36 | $-0.35 | $-0.32 | $-0.35 | $-0.38 | $-0.27 | $-0.28 | $-0.36 | $-0.30 | $-0.26 | $-0.26 | $-0.26 | $-0.31 |
| Low Forecast | $-0.31 | $-0.33 | $-0.34 | $-0.40 | $-0.37 | $-0.42 | $-0.39 | $-0.42 | $-0.59 | $-0.37 | $-0.41 | $-0.42 | $-0.39 | $-0.47 | $-0.45 | $-0.38 | $-0.36 | $-0.33 | $-0.37 | $-0.40 | $-0.28 | $-0.29 | $-0.38 | $-0.31 | $-0.27 | $-0.27 | $-0.28 | $-0.32 |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.94% | 0.90% | 1.05% | 0.88% | 0.71% | - | 1.35% | 1.23% | 1.23% | 0.85% | 0.79% | 1.75% | 1.09% | 0.87% | 1.04% | 1.01% | 0.96% | 1.54% | 2.66% |
According to undefined Wall Street analysts, Silk Road Medical's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to SILK previous annual EPS of $NaN (undefined).
Silk Road Medical Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| OFIX | Orthofix Medical | $16.22 | $31.00 | 91.12% | - |
| NPCE | NeuroPace | $6.96 | $12.88 | 85.06% | Buy |
| FNA | Paragon 28 | $6.94 | $11.50 | 65.71% | Buy |
| NARI | Inari Medical | $44.10 | $70.33 | 59.48% | Buy |
| SGHT | Sight Sciences | $6.83 | $10.33 | 51.24% | Hold |
| LUNG | Pulmonx | $8.18 | $12.25 | 49.76% | Buy |
| LIVN | LivaNova | $51.00 | $70.20 | 37.65% | Buy |
| KIDS | OrthoPediatrics | $31.08 | $40.80 | 31.27% | Buy |
| SIBN | SI-BONE | $15.68 | $20.00 | 27.55% | Buy |
| RXST | RxSight | $56.14 | $68.60 | 22.19% | Buy |
| SILK | Silk Road Medical | $27.49 | $30.58 | 11.24% | Buy |
| TMDX | TransMedics Group | $156.08 | $156.86 | 0.50% | Buy |
SILK Forecast FAQ
Is Silk Road Medical a good buy?
Yes, according to 7 Wall Street analysts, Silk Road Medical (SILK) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 4 'Buy' recommendations, accounting for 57.14% of SILK's total ratings.
What is SILK's price target?
Silk Road Medical (SILK) average price target is $30.58 with a range of $20 to $46, implying a 11.24% from its last price of $27.49. The data is based on 7 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Silk Road Medical stock go up soon?
According to Wall Street analysts' prediction for SILK stock, the company can go up by 11.24% (from the last price of $27.49 to the average price target of $30.58), up by 67.33% based on the highest stock price target, and down by -27.25% based on the lowest stock price target.
Can Silk Road Medical stock reach $40?
SILK's highest twelve months analyst stock price target of $46 supports the claim that Silk Road Medical can reach $40 in the near future.
What are Silk Road Medical's analysts' financial forecasts?
Silk Road Medical's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $194.07M (high $200.08M, low $189.62M), average EBITDA is $-78.616M (high $-74.051M, low $-83.602M), average net income is $-60.637M (high $-54.76M, low $-66.986M), average SG&A $165.1M (high $174.66M, low $156.46M), and average EPS is $-1.511 (high $-1.435, low $-1.605). SILK's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $221.74M (high $229.58M, low $216.7M), average EBITDA is $-93.55M (high $-91.423M, low $-96.854M), average net income is $-52.201M (high $-50.657M, low $-54.597M), average SG&A $204.42M (high $211.64M, low $199.78M), and average EPS is $-1.317 (high $-1.279, low $-1.378).
Did the SILK's actual financial results beat the analysts' financial forecasts?
Based on Silk Road Medical's last annual report (Dec 2022), the company's revenue was $138.64M, beating the average analysts forecast of $128.88M by 7.57%. Apple's EBITDA was $-49.667M, missing the average prediction of $-51.691M by -3.92%. The company's net income was $-58.016M, beating the average estimation of $-57.229M by 1.38%. Apple's SG&A was $116.32M, beating the average forecast of $105.22M by 10.55%. Lastly, the company's EPS was $-1.62, missing the average prediction of $-1.649 by -1.73%. In terms of the last quarterly report (Sep 2023), Silk Road Medical's revenue was $44.44M, missing the average analysts' forecast of $44.53M by -0.21%. The company's EBITDA was $-13.671M, missing the average prediction of $-18.786M by -27.23%. Silk Road Medical's net income was $-12.788M, missing the average estimation of $-13.968M by -8.45%. The company's SG&A was $36.01M, missing the average forecast of $41.05M by -12.28%. Lastly, the company's EPS was $-0.33, missing the average prediction of $-0.353 by -6.39%